OncoMatch/Clinical Trials/NCT07193641
A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC
Is NCT07193641 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies The systemic therapy for non small cell lung cancer.
Treatment: The systemic therapy — The goal of this clinical trial is to learn if spatially fractionated radiotherapy (SFRT) combined with standard systemic therapy can treat oligoprogressive non-small cell lung cancer (NSCLC) in patients who have progressed after at least one line of systemic therapy. The main question it aims to answer is: \- Can the combination of SFRT and standard systemic therapy improve progression-free survival (PFS) compared to standard systemic therapy alone? Participants will: * Undergo SFRT treatment for oligoprogressive lesions, with specific dose fractionation determined by the radiation oncologist based on clinical parameters. * Continue their standard systemic therapy, which may include chemotherapy, targeted therapy, or immunotherapy, as adjusted by their treating physician. * Have regular follow-up assessments, including imaging studies to evaluate treatment response and monitor for disease progression.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy
having received and progressed after at least one line of systemic therapy (chemotherapy, targeted therapy, or immunotherapy)
Must have received: targeted therapy
having received and progressed after at least one line of systemic therapy (chemotherapy, targeted therapy, or immunotherapy)
Must have received: immunotherapy
having received and progressed after at least one line of systemic therapy (chemotherapy, targeted therapy, or immunotherapy)
Lab requirements
Blood counts
hemoglobin ≥9.0 g/dL, ANC ≥1500/mm³, platelet count ≥100,000/mm³
Kidney function
creatinine ≤1.5x ULN (or GFR >60 mL/min if creatinine >1.5x ULN)
Liver function
total bilirubin ≤1.5x ULN (or direct bilirubin ≤ULN if total bilirubin >1.5x ULN), ALT and AST ≤2.5x ULN (or ≤5x ULN if liver involvement is present)
Adequate hematologic and biochemical profiles, including hemoglobin ≥9.0 g/dL, absolute neutrophil count (ANC) ≥1500/mm³, platelet count ≥100,000/mm³, total bilirubin ≤1.5 times the upper limit of normal (ULN) (or direct bilirubin ≤ULN if total bilirubin >1.5 times ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times ULN (or ≤5 times ULN if liver involvement is present), and creatinine ≤1.5 times ULN (or glomerular filtration rate [GFR] >60 mL/min if creatinine >1.5 times ULN).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify